Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
3 reports, 2 independent
Updated Sep 24
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Sub-event
Report details clinical trials for Mycosis Fungoides involving major pharmaceutical companies.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
Merck
public company in Indonesia
Nothing else this week.
-
Novartis
Swiss-American multinational pharmaceutical corporation
Related events
Coverage
Newest first; wire copies grouped- prnewswire.com
- GlobeNewswireMycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON Discover key insights